THERAPY DOSSIER · th-a4c98a478b23

MTDQ, 6,6-methylene-bis(2,2,4-trimethyl-1,2-dihydroquinoline), and MDS, 6,6-methylene-bis(2,2-dimethyl-4-methanesulphonic acid sodium-1,2-dihydroquinoline)

Drug · Combination of two synthetic dihydroquinoline antioxidants (MTDQ and MDS); no single ChEMBL entity.

Evidence & regulatory context

Mechanism: Combination of two synthetic dihydroquinoline antioxidants (MTDQ and MDS); no single ChEMBL entity.
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 7150502 ↗1982Reported benefit

Biochemical markers in carbon-tetrachloride-and galactosamine-induced acute liver injuries: the effects of dihydroquinoline-type antioxidants.

MouseChemical/toxinCFLP

Model: Carbon tetrachloride-induced and galactosamine-induced acute liver injury

The lipid-soluble MTDQ prevented carbon tetrachloride-induced injury and the water-soluble MDS prevented galactosamine-induced injury, with disappearance or significant reduction of lipid degeneration and centrilobular necrosis, reduced serum GOT activity, and reduced galactosamine-induced inflamma…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…